

Izmantotais literatūras saraksts prezentācijai IVP sēdē 12.06.2024. par iespēju pāriet uz vienas devas shēmu vakcinācijai pret CPV.

1. Barnabas RV, Brown ER, Onono M, et al. Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial. *Trials*. 2021;22(1):661. Published 2021 Sep 27. doi:10.1186/s13063-021-05608-8

Links: <https://pubmed.ncbi.nlm.nih.gov/34579786/>

2. Watson-Jones D, Changalucha J, Whitworth H, et al. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. *Lancet Glob Health*. 2022;10(10):e1473-e1484. doi:10.1016/S2214-109X(22)00309-6

Links: <https://pubmed.ncbi.nlm.nih.gov/36113531/>

3. Baisley K, Kemp TJ, Mugo NR, Whitworth H, Onono MA, Njoroge B, Indangasi J, Bukusi EA, Prabhu PR, Mutani P, Galloway DA, Mwanzalime D, Kapiga S, Lacey CJ, Hayes RJ, Changalucha J, Pinto LA, Barnabas RV, Watson-Jones D. Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose in young women aged 15-20 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials. *Lancet Glob Health*. 2024 Mar;12(3):e491-e499. doi: 10.1016/S2214-109X(23)00586-7. PMID: 38365419; PMCID: PMC10882205

Links: [https://www.thelancet.com/journals/langlo/article/PIIS2214-109X\(23\)00586-7/fulltext](https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(23)00586-7/fulltext)

4. Kreimer AR, Sampson JN, Porras C, et al. Evaluation of Durability of a Single Dose of the Bivalent HPV Vaccine: The CVT Trial. *J Natl Cancer Inst*. 2020;112(10):1038-1046. doi:10.1093/jnci/djaa011

Links: <https://pubmed.ncbi.nlm.nih.gov/32091594/>

5. Basu P, Malvi SG, Joshi S, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study [published correction appears in *Lancet Oncol*. 2022 Jan;23(1):e16]. *Lancet Oncol*. 2021;22(11):1518-1529. doi:10.1016/S1470-2045(21)00453-8

Links: <https://pubmed.ncbi.nlm.nih.gov/34634254/>

6. Bénard É, Drolet M, Laprise JF, Gingras G, Jit M, Boily MC, Bloem P, Brisson M. Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis. *Lancet Public Health*. 2023 Oct;8(10):e788-e799. doi: 10.1016/S2468-2667(23)00180-9. PMID: 37777288; PMCID: PMC10557953

Links: [https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667\(23\)00180-9/fulltext](https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(23)00180-9/fulltext)